Published in Cancer Res on June 01, 1992
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Res (1987) 0.93
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res (1993) 0.78
Induction of suppressor T cells in culture--I. Cell-cell interactions. Int J Immunopharmacol (1984) 0.78
The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol (1983) 0.78
Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res (1975) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol (1993) 0.78
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol (1995) 0.78
Selective effects of Adriamycin on murine host defense systems. Immunol Rev (1982) 0.78
Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res (1999) 0.78
Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods. J Natl Cancer Inst (1979) 0.77
Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol Res (1994) 0.77
Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res (1981) 0.77
In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function. Methods Find Exp Clin Pharmacol (1987) 0.77
Selectivity of inhibition by anticancer agents of mouse spleen immune effector functions involved in responses to sheep erythrocytes. Cancer Res (1978) 0.77
Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice. Cancer Res (1971) 0.77
Immunomodulating effects of anticancer drugs: the example of adriamycin. Transplant Proc (1984) 0.77
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res (1995) 0.77
Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine. Cancer Res (1980) 0.77
Selective imbalances of cellular immune responses by adriamycin. Recent Results Cancer Res (1980) 0.76
Antitumor effects of kethoxal-bis(thiosemicarbazone) and 6-mercaptopurine in neonatally thymectomized mice. Proc Soc Exp Biol Med (1967) 0.76
RNA recovery efficiency for cultured cells and organ-derived cell suspensions. Nucleic Acids Res (1994) 0.75
The relationship of blood vessel proximity and time after radiolabeled thymidine administration to tumor cell population kinetics in a transplanted mouse mammary tumor. Am J Pathol (1981) 0.75
Kethoxal bis(thiosemicarbazone). II. Toxic and pathologic effects. Cancer Res (1965) 0.75
Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. Natl Cancer Inst Monogr (1971) 0.75
Antitumor effects of methylglyoxal-bis(N-4-methylthiosemicarbazone) and their potentiation in pyridoxine-deficient animals. Cancer Res (1965) 0.75
Low concentrations of thymidine modulate allogeneic responses. Int J Immunopharmacol (1987) 0.75
Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro. J Immunol (1977) 0.75
Biological response modifiers: their potential and limitations in cancer therapeutics. Cancer Invest (1985) 0.75
Determinants of response in cancer chemotherapy and modulation of anticancer activity. Cancer Treat Rev (1984) 0.75
Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune response in mouse model systems. Biochem Pharmacol (1982) 0.75
International symposium on molecular basis for cancer chemo- and immuno-prevention: meeting report, meeting held at Shanghai, China, Nov 29-Dec 1 2001. J Cancer Res Clin Oncol (2002) 0.75
Multiple basis of combination chemotherapy. Cancer (1977) 0.75
Effect of antimyeloma cell antiserum on immunological enhancement. Cancer Res (1975) 0.75
Multifactorial cellular determinants of the action of antimetabolites. Adv Enzyme Regul (1976) 0.75
Time limitations in the reversal by citrovorum factor of methotrexate-induced immunosuppression in mice. Biochem Pharmacol (1977) 0.75
Future perspectives for biological response modifiers: a viewpoint. Semin Oncol (1986) 0.75
Immunomodulation by adriamycin. Sci Rep Res Inst Tohoku Univ Med (1985) 0.75
Studies on the structure--activity relationship among aliphatic and aromatic bisguanylhydrazones and some related compounds. Chem Biol Interact (1977) 0.75
Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin. Immunopharmacology (1982) 0.75
Bone marrow determination of complement dependent and complement independent cellular cytotoxcity. Cell Immunol (1975) 0.75
Modification by biological products of the generation of suppressor cells in culture. Immunopharmacology (1983) 0.75
The differential sensitivity of T cell immune functions to vincristine and vinblastine. Int J Immunopharmacol (1982) 0.75
Molecular aspects of growth control. An extended report on the first joint meeting of the AACR and the Japanese Cancer Association. Cancer Res (1989) 0.75
Selective effects of methylglyoxal-bis-(guanylhydrazone) on the development of antibody-forming cells in mice. Biochem Pharmacol (1977) 0.75
Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs. Cancer Res (1982) 0.75
Mouse effector functions involved in the antibody-dependent cellular cytotoxicity to xenogeneic erythrocytes. J Immunol (1975) 0.75
Mechanism of the inhibition of DNA biosynthesis by 4,4'-diacetyldiphenylurea-bis(guanylhydrazone) in leukemia L1210 cells. Cancer Res (1973) 0.75
Study of the immune responses to nucleated cells. I. In vitro functional evaluation of the immune effectors responsible for complement-dependent cellular cytotoxicity. Cell Immunol (1973) 0.75
Spectrophotometric studies on the binding with polynucleotides of 4,4'-diacetyldiphenylurea-bis(guanylhydrazone) and methylglyoxal-bis(guanylhydrazone). Chem Biol Interact (1976) 0.75
Role of cellular antigens in humoral and cell-mediated immunity as measured in vitro. Proc Soc Exp Biol Med (1973) 0.75
Induction of suppressor T cells in culture--II. Modification by adriamycin. Int J Immunopharmacol (1984) 0.75
The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model. Cancer Commun (1990) 0.75
Clinical biochemical pharmacology of anticancer antimetabolites: introductory remarks. Bull Cancer (1979) 0.75
Inhibition of suppressor cell generation by mouse serum in culture. Int J Immunopharmacol (1986) 0.75
Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. Cancer Res (1987) 0.75
Immunosuppression in cancer therapeutics. Transplant Proc (1975) 0.75
International symposium on new leads in experimental and clinical gene targeting in cancer. J Cancer Res Clin Oncol (2003) 0.75
The effects of dichloro-trans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology (1983) 0.75